Ingredients | Amount Per Serving |
---|---|
(Adenosine 5'-Triphosphate Disodium Salt)
|
400 mg |
(root)
(as Eurycoma longifolia)
(Longjack extract (Form: as Eurycoma longifolia Genus: Eurycoma Species: longifolia) PlantPart: root )
|
100 mg |
Maltodextrin, Capsule (Form: Bovine Gelatin, Titanium Dioxide, Water), Magnesium Stearate, Silicon Dioxide (Alt. Name: SiO2)
Below is general information about the effectiveness of the known ingredients contained in the product Peak SX-7. Some ingredients may not be listed. This information does NOT represent a recommendation for or a test of this specific product as a whole.
INSUFFICIENT RELIABLE EVIDENCE to RATE
INSUFFICIENT RELIABLE EVIDENCE to RATE
Below is general information about the safety of the known ingredients contained in the product Peak SX-7. Some ingredients may not be listed. This information does NOT represent a recommendation for or a test of this specific product as a whole.
LIKELY SAFE ...when adenosine is used intravenously and appropriately. Adenosine injection (Adenocard, Adenoscan) is an FDA-approved prescription drug (15).
POSSIBLY SAFE ...when adenosine triphosphate (ATP) is used intravenously and appropriately. ATP appears to be safe in intravenous doses of 75 mcg/kg per minute for 30 hours given every 2 weeks for 28 weeks (9149,9154). There is insufficient reliable information available about the safety of adenosine when used orally or intramuscularly.
PREGNANCY AND LACTATION:
Insufficient reliable information available; avoid using.
POSSIBLY SAFE ...when used orally and appropriately in medicinal amounts. Eurycoma longifolia has been safely used in doses of 400 mg daily for up to 3 months and in doses of 200 mg daily for up to 9 months (17924,18138,93490,97312).
POSSIBLY UNSAFE ...when used orally in excessive amounts, long-term. There are some concerns about the safety of Eurycoma longifolia due to contamination with mercury and lead or adulteration with sildenafil (17925,17926,17927,18137,49087,93494). Some research shows that 36% and 17% of Eurycoma longifolia preparations from Malaysia contain high levels of mercury and lead, respectively (17925,17926,17927,49087). While safety issues related to these contaminants have not been reported in humans, taking high doses of Eurycoma longifolia long-term might cause symptoms of heavy metal poisoning or sildenafil-related adverse effects.
PREGNANCY AND LACTATION:
Insufficient reliable information available; avoid using.
Animal research suggests that there are no negative effects of Eurycoma longifolia on the offspring (93493). However, research in humans is lacking.
Below is general information about the interactions of the known ingredients contained in the product Peak SX-7. Some ingredients may not be listed. This information does NOT represent a recommendation for or a test of this specific product as a whole.
Carbamazepine might increase the risk of heart block when used concomitantly with adenosine.
Details
Carbamazepine and adenosine can both cause heart block. Giving them concurrently might produce an additive effect (15).
|
Dipyridamole can increase the therapeutic and toxic effects of adenosine.
Details
Dipyridamole decreases the metabolism of adenosine. Intravenous infusion of adenosine in patients who are taking dipyridamole can cause dizziness, bradycardia, and syncope. Dipyridamole should be discontinued for several days prior to a cardiac stress test using adenosine (12209).
|
Methylxanthines are competitive antagonists of adenosine and can block its pharmacologic effects.
Details
|
Theoretically, Eurycoma longifolia might increase levels CYP1A2 substrates.
Details
In vitro research suggests that methanolic Eurycoma longifolia root extract weakly inhibits CYP1A2 enzymes (93489). This effect has not been reported in humans.
|
Theoretically, Eurycoma longifolia might increase levels of CYP2A6 substrates.
Details
In vitro research suggests that methanolic Eurycoma longifolia root extract weakly inhibits CYP2A6 enzymes (93489). This effect has not been reported in humans.
|
Theoretically, Eurycoma longifolia might increase levels of CYP2C19 substrates.
Details
In vitro research suggests that methanolic Eurycoma longifolia root extract weakly inhibits CYP2C19 enzymes (93489). This effect has not been reported in humans.
|
Eurycoma longifolia can reduce the levels and clinical effects of propranolol.
Details
A small clinical study in healthy persons shows that taking a single dose of a water-based Eurycoma longifolia extract 200 mg, in combination with a single dose of propranolol 80 mg, reduces the propranolol area under the curve (AUC) by 29%, reduces the peak concentration by 42%, and increases time to peak concentration by 86% when compared with control. Since the elimination half-life of propranolol did not change, it seems that Eurycoma longifolia alters the kinetics of propranolol by decreasing its absorption in the gut, and not by altering its metabolism (17923). It is not known if separating administration will prevent this interaction.
|
Theoretically, Eurycoma longifolia may further increase levels of testosterone.
Details
A clinical study in aging males with testosterone levels below 300 ng/dL shows that taking a specific water extract of Eurycoma longifolia roots (Physta; Biotropics Malaysia) 100-200 mg daily with breakfast for 12 weeks increases total testosterone levels by 8% to 11% when compared with placebo (108451). It is unclear whether this increase would occur in individuals with normal testosterone levels.
|
Below is general information about the adverse effects of the known ingredients contained in the product Peak SX-7. Some ingredients may not be listed. This information does NOT represent a recommendation for or a test of this specific product as a whole.
General
...Intravenously, the prescription form of adenosine can cause cardiovascular and respiratory adverse effects.
When used orally or intramuscularly, no adverse effects have been reported; however, a thorough evaluation of safety outcomes has not been conducted.
Most Common Adverse Effects:
Intravenously: Chest pain, dizziness, dyspnea, facial flushing, headache, hypotension, nausea, nervousness, numbness, paresthesias, and tingling.
Serious Adverse Effects (Rare):
Intravenously: Arrhythmias, first- and second-degree heart block, hypersensitivity reactions, myocardial infarction, ST segment depression, and ventricular tachycardia.
Cardiovascular ...Intravenously, adenosine causes chest pain, palpitations, hypotension, and supraventricular tachycardia (15,9148). Intravenous adenosine has also been associated with arrhythmias, fatal or nonfatal cardiac arrest, ventricular tachycardia, and myocardial infarction (15). Intravenously, adenosine triphosphate (ATP) causes chest pain, particularly at doses greater than 50 mcg/kg per minute (9154).
Dermatologic ...Intravenously, adenosine causes flushing in up to 44% of patients in clinical research (15). Topically, folliculitis and pruritus can occur after application of adenosine to the scalp (93689).
Gastrointestinal ...Intravenously, adenosine can cause abdominal discomfort (15).
Neurologic/CNS ...Rapid intravenous injection of adenosine can cause headache, lightheadedness, insomnia, and anxiety (9148,9151,9152,9154,9158). New onset seizures, including tonic-clonic seizures, have also occurred (15). Intrathecally, adenosine has been reported to cause headache (9157).
Pulmonary/Respiratory ...Intravenously, adenosine can cause dyspnea, bronchospasm, bronchoconstriction, and respiratory arrest (15). Intravenously, adenosine triphosphate (ATP) causes dyspnea, which can be severe, particularly at doses greater than 50 mcg/kg/minute (9154).
General
...Orally, Eurycoma longifolia seems to be well tolerated.
Most Common Adverse Effects:
Orally: None reported.
Endocrine ...Some research in both humans and animals suggests that Eurycoma longifolia might increase testosterone levels (17924). If testosterone levels are increased beyond the normal range, there is risk of testosterone-related side effects which could include acne, insulin resistance, hepatotoxicity, and others.